In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Opens Up: Can Industry Live With Greater Transparency?

Executive Summary

Drug sponsors are finding little to like about FDA’s transparency initiative - especially proposals that would allow the agency to disclose more about products still in development. But given the public interest in greater transparency - and FDA’s interest in avoiding another Avandia - industry needs to decide whether this is a fight worth having. This article was originally published in the July/August 2010 issue of The RPM Report.
Advertisement

Related Content

Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public
The FDA Roundtable Part I: The Regulators' View of Drug Development
The FDA Roundtable Part I: The Regulators' View of Drug Development
Tracking Troubled NDAs: New FDA Regs Mean Less Clarity for Investors
Tracking Troubled NDAs: New FDA Regs Mean Less Clarity for Investors
A New Phase for Phase IV: Post-marketing Studies Won't Be the Same After Drug Safety Bill
A New Phase for Phase IV: Post-marketing Studies Won't Be the Same After Drug Safety Bill

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel